Abstract 1602P
Background
CBP-1018 is a first-in-class bi-ligand-drug conjugate targeting both PSMA and FRα with monomethyl auristatin E (MMAE) as the payload. Preclinical studies have shown that CBP-1018 with a MW of only 3 KD can deliver more payloads than MMAE ADCs with a favorable safety profile. In the Phase I study (NCT04928612), CBP-1018 had showed well-tolerated safety profiles and preliminary anti-tumor activity in patients (pts) with advanced solid tumors.
Methods
This ongoing Phase I study consists of several stages. The design of the dose escalation stage is an accelerated titration at 0.03 mg/kg Q2W following by a standard “3+3” from 0.06 to 0.16 mg/kg. The dose expansion stage is conducted at selected dose levels. The primary endpoints are safety, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), objective response rate (ORR) and PFS.
Results
By 9th Mar, 2024, a total of 93 pts were enrolled (21 pts for dose escalation, and 72 pts for dose expansion at 0.12, 0.14 and 0.16 mg/kg). 97.8% of the pts had mCRPC. No DLT was observed and the MTD was not yet reached. The median age was 69 (range:50-78). The median number of prior treatments was 7 (68.8% pts with prior chemotherapy). Most treatment-related adverse events (TRAEs) were grade 1 or 2. Grade ≥3 TRAEs mainly included neutrophil count decreased (44.1%), WBC count decreased (20.4%), hypokalaemia (15.1%). No ocular toxicity was observed. There were only 4 (4.3%) pts experienced TRAE leading to dose reduction without any TRAE leading to death. Among all mCRPC pts with target lesions, dose levels ≥0.14 mg/kg show better efficacy: 20% ORR and 80% DCR based on RECIST v1.1 in 15 efficacy evaluable pts with target lesions in ≥0.14 mg/kg dose levels. And the median radiographic progression-free survival (rPFS) was 7 months and over 40% of them experienced PSA decreased. The exposure of CBP-1018 and free MMAE increased with dose escalation.
Conclusions
CBP-1018, as the first bi-XDC globally, has showed a promising preliminary efficacy and well-tolerated safety profile in mCRPC pts, supporting a further investigation in mCRPC pts to decide optimal dose and further confirmation in a large scale population. Yehui Shi and Hai Huang are the corresponding authors.
Clinical trial identification
NCT04928612.
Editorial acknowledgement
Legal entity responsible for the study
Coherent Biopharma.
Funding
Has not received any funding.
Disclosure
R. Huang, M. Xu, B. Pan, J. Zhang: Financial Interests, Personal, Full or part-time Employment: Coherent Biopharma. All other authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10